Happy Science Friday Everyone.
It makes me happy to see someone who loves laminar flow as much as I do.
This review provides an essence of some newly developed simple but prospective strategies on enhancing the efficacy of drugs/bioactive molecules exploiting various drug delivery systems like micelles, cyclodextrins, liposomes etc. to serve the purpose of targeted delivery towards DNA, by endogenous and/or exogenous means.I think the coolest part though is the concept of adsorption and how these could potentially scrub the body of unwanted molecules. Could this be applied to systematic free drug in order to decrease offsite toxicity?
On May 3, 2019, the Food and Drug Administration approved ado-trastuzumab emtansine (KADCYLA, Genentech, Inc.) for the adjuvant treatment of patients with HER2-positive early breast cancer (EBC) who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.